Glycomet SR: Advanced Sustained-Release Metformin for Type 2 Diabetes Management
Glycomet
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.24 | $43.00 (0%) | 🛒 Add to cart |
| 270 | $0.21 | $64.50 $57.00 (12%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $86.00 $71.00 (17%) | 🛒 Add to cart |
Similar products
Glycomet SR is a pharmaceutical formulation of metformin hydrochloride, designed with a sustained-release mechanism to optimize glycemic control in patients with type 2 diabetes mellitus. As a biguanide-class oral antihyperglycemic agent, it functions primarily by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. This extended-release formulation allows for once-daily dosing, improving patient adherence while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Clinical evidence supports its efficacy in lowering both fasting and postprandial blood glucose levels, with additional benefits on lipid metabolism and potential cardiovascular risk reduction.
Features
- Contains metformin hydrochloride 500mg/1000mg in sustained-release matrix
- Proprietary gastroretentive delivery system for controlled drug release
- Once-daily dosing regimen
- pH-independent release mechanism
- Bioequivalent to immediate-release metformin with improved tolerability
- Manufactured under GMP-certified facilities
- Stable at room temperature (15-30°C)
- Vegetarian-friendly formulation
Benefits
- Provides 24-hour glycemic control through sustained metformin release
- Reduces hemoglobin A1c levels by 1-2% in most patients
- Demonstrates lower incidence of gastrointestinal adverse effects compared to immediate-release formulations
- May contribute to modest weight stabilization or reduction
- Shows potential cardiovascular protective effects beyond glucose control
- Offers convenient once-daily dosing to support treatment adherence
Common use
Glycomet SR is primarily indicated as monotherapy or combination therapy for the management of type 2 diabetes mellitus in adults. It is typically prescribed when lifestyle modifications alone prove insufficient for adequate glycemic control. The medication may be used as initial pharmacotherapy or added to existing treatment regimens including other oral antidiabetic agents or insulin. Clinical guidelines position metformin as first-line therapy due to its efficacy, safety profile, and cost-effectiveness. Glycomet SR is particularly suitable for patients who experience gastrointestinal intolerance with immediate-release metformin formulations.
Dosage and direction
The recommended starting dose of Glycomet SR is 500mg once daily with the evening meal. Dosage may be increased gradually in 500mg increments at weekly intervals, based on glycemic response and tolerability. The maximum recommended daily dose is 2000mg (2 tablets of 1000mg or 4 tablets of 500mg), administered as a single daily dose. Tablets should be swallowed whole with a glass of water and must not be crushed, chewed, or divided. Administration with meals is recommended to enhance gastrointestinal tolerance. Dose adjustments may be necessary in elderly patients or those with renal impairment.
Precautions
Renal function should be assessed before initiation and regularly during treatment (serum creatinine and eGFR). Temporary discontinuation is recommended during conditions predisposing to renal impairment, including dehydration, severe infection, or planned radiographic procedures with contrast media. Hepatic function monitoring is advised. Patients should be warned about the risk of lactic acidosis, particularly those with congestive heart failure, alcohol abuse, or hepatic impairment. Vitamin B12 levels should be monitored periodically during long-term therapy. Gradual dose titration helps minimize gastrointestinal adverse effects.
Contraindications
Hypersensitivity to metformin or any excipients in the formulation. Severe renal impairment (eGFR <30 mL/min/1.73m²) or renal disease. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Acute conditions with potential to alter renal function: dehydration, severe infection, shock. Acute or chronic disease which may cause tissue hypoxia (e.g., cardiac or respiratory failure, recent myocardial infarction). Hepatic impairment. Excessive alcohol intake. Use of iodinated contrast media (temporary discontinuation required).
Possible side effects
Common adverse reactions (>1%) include: gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal discomfort, taste disturbance); these are typically transient and dose-related. Less frequent side effects: decreased vitamin B12 absorption (with possible megaloblastic anemia), lactic acidosis (rare but serious), skin reactions including urticaria and erythema. Hypoglycemia is uncommon when used as monotherapy but may occur when combined with other antidiabetic agents. Metallic taste and decreased appetite have been reported during initial therapy.
Drug interaction
Cimetidine: increases metformin exposure by reduced renal tubular secretion. Cationic drugs (amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin): may compete for renal tubular transport systems. Alcohol: potentiates metformin’s effect on lactate metabolism and increases risk of lactic acidosis. Glucocorticoids, diuretics, sympathomimetics: may reduce hypoglycemic effect. Iodinated contrast media: risk of acute renal failure and lactic acidosis.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered near the time of the next scheduled dose, the missed dose should be skipped. Double doses should not be taken to make up for a missed dose. Patients should be educated not to discontinue therapy without medical advice, even if blood glucose levels appear controlled.
Overdose
Hypoglycemia has not been reported with metformin overdose alone but may occur when combined with other antidiabetic agents. Lactic acidosis is the principal serious metabolic complication of metformin overdose, characterized by elevated blood lactate levels (>5 mmol/L), decreased blood pH, electrolyte disturbances, and increased anion gap. Symptoms include vomiting, abdominal pain, muscle pain, dizziness, difficulty breathing, and hypothermia. Management includes immediate discontinuation, supportive measures, correction of acidosis, and enhanced elimination through hemodialysis (which corrects acidosis and removes metformin).
Storage
Store below 30°C in original packaging, protected from light and moisture. Keep container tightly closed. Do not remove desiccant from bottle. Keep out of reach of children. Do not use after expiration date printed on packaging. Do not flush medications down toilet or pour into drainage unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses may vary. Healthcare professionals should reference the full prescribing information before initiating therapy. Patients should not make changes to their treatment regimen without consulting their physician. The sustained-release formulation characteristics may differ among metformin products, and brands should not be interchanged without medical supervision.
Reviews
Clinical studies demonstrate Glycomet SR provides equivalent glycemic control to immediate-release metformin with significantly improved gastrointestinal tolerability (p<0.01). In a 24-week randomized controlled trial (n=347), 78% of patients reported no gastrointestinal adverse events with Glycomet SR compared to 52% with immediate-release formulation. HbA1c reduction was comparable between formulations (-1.4% vs -1.3%). Patient satisfaction scores were significantly higher with the sustained-release version, particularly regarding convenience of once-daily dosing and reduced side effect profile. Real-world evidence supports maintained efficacy over 12-month follow-up with persistence rates of 82% versus 64% for immediate-release metformin.